Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens

Paterson, Yvonne; Johnson, Ross S.

doi:10.1586/14760584.3.4.s119

Cited by 38 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to note that L. monocytogenes has been used as a vector for heterologous antigens and has been shown to induce regression of established syngeneic tumors in mouse models following systemic administration. For these reasons, L. monocytogenes is under active investigation as an antigen-specific vaccine vector for cancer and infectious disease (21,26). The major focus of this work, however, is to exploit the ability of L. monocytogenes to target an immune response to the liver rather than its ability to generate an antigen-specific vaccine response by itself.…”

Section: Discussionmentioning

confidence: 99%

Selective Targeting of Antitumor Immune Responses with Engineered Live-Attenuated Listeria monocytogenes

et al. 2006

View full text Add to dashboard Cite

Improved immunization and ex vivo T-cell culture strategies can generate larger numbers and more potent tumor-specific effector cells than previously possible. Nonetheless, the capacity of these cells to eliminate established tumors is limited by their ability to efficiently enter tumor-bearing organs and mediate their effector function. In the current study, we show that the administration of an engineered organ-homing microbe selectively targets tumor-specific immune responses to metastases within that organ. Specifically, an attenuated Listeria monocytogenes strain, which preferentially infects the liver following systemic administration, dramatically enhances the activity of a cancer vaccine against liver metastases but not metastases in the lung. This enhanced activity results from both local recruitment of innate immune effectors as well as concentration and increased activation of vaccine-induced antitumor T cells within the liver. These findings show a general approach to focus systemic cancer immunotherapies to specific organs bearing tumor metastases by taking advantage of differential tropisms and the proinflammatory nature of microbes.

show abstract

Section: Discussionmentioning

confidence: 99%

Selective Targeting of Antitumor Immune Responses with Engineered Live-Attenuated Listeria monocytogenes

et al. 2006

View full text Add to dashboard Cite

show abstract

“…MHC class II molecules present peptides derived from listerial proteins in the phagolysosome to activate CD4 ϩ T cells (16). Conversely, proteins that are produced by L. monocytogenes in the host cytosol are presented to CD8 ϩ T cells by MHC class I molecules (17,18). Taking advantage of the ability of L. monocytogenes to target Ags to both of these pathways should lead to a strong cellular immune response against the Ags it produces.…”

mentioning

confidence: 99%

Fusion to Listeriolysin O and Delivery by Listeria monocytogenes Enhances the Immunogenicity of HER-2/neu and Reveals Subdominant Epitopes in the FVB/N Mouse

Singh

Dominiecki

Jaffee³

et al. 2005

The Journal of Immunology

Self Cite

103

134

View full text Add to dashboard Cite

Five overlapping fragments of rat HER-2/neu have been expressed in recombinant Listeria monocytogenes. Each fragment of HER-2/neu is secreted as a fusion protein with a truncated, nonhemolytic form of listeriolysin O (LLO). Lm-LLO-EC1, Lm-LLO-EC2, and Lm-LLO-EC3 overlap the extracellular domain of HER-2/neu, whereas Lm-LLO-IC1 and Lm-LLO-IC2 span the intracellular domain. All five strains controlled the growth of established NT-2 tumors, a rat HER-2/neu-expressing tumor line derived from a spontaneously arising mammary tumor in a FVB/N HER-2/neu-transgenic mouse. The antitumor effect of each of these vaccine constructs was abrogated by the in vivo depletion of CD8+ T cells, although only one known epitope has been defined previously and is present in Lm-LLO-EC2. Anti-HER-2/neu CTL responses were generated by each of the rLm vaccine constructs. With the use of a panel of 3T3 cell lines expressing overlapping fragments of HER-2/neu, regions of HER-2/neu with potential CD8+ T cell epitopes have been defined. DNA vaccines expressing either a fragment or full-length HER-2/neu were constructed in LLO-fused and non-LLO-fused forms. CTL analysis of the DNA vaccines revealed a broadening in the regions of HER-2/neu recognizable as targets when the target Ag is fused to LLO. These studies show the efficacy of L. monocytogenes-based HER-2/neu vaccines in a murine model of breast cancer and also that the immunogenicity of self-Ags can be increased by fusion to LLO and delivery by L. monocytogenes revealing subdominant epitopes.

show abstract

“…Her work demonstrated that a recombinant L. monocytogenes that expressed and secreted the model antigen influenza virus nucleoprotein (NP) fused to LLO could efficiently infect APCs, and this expressed NP protein was processed by the endogenous antigen-processing pathway, facilitating the presentation of NP epitopes in the context of MHC class I molecules. 10 Since then, the L. monocytogenes platform has rapidly evolved to become one of the most efficacious approaches for antigen delivery for infectious diseases 11 and cancer (For a review see. 12 ) Salmonella is a gram-negative bacterium and intracellular pathogen that causes salmonellosis.…”

Section: Bacterial Vectors For Active Immunotherapy Reach Clinical Anmentioning

confidence: 99%

Bacterial vectors for active immunotherapy reach clinical and industrial stages

Gouëllec

Chauchet

Polack

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens

Cited by 38 publications

References 42 publications

Selective Targeting of Antitumor Immune Responses with Engineered Live-Attenuated Listeria monocytogenes

Selective Targeting of Antitumor Immune Responses with Engineered Live-Attenuated Listeria monocytogenes

Fusion to Listeriolysin O and Delivery by Listeria monocytogenes Enhances the Immunogenicity of HER-2/neu and Reveals Subdominant Epitopes in the FVB/N Mouse

Bacterial vectors for active immunotherapy reach clinical and industrial stages

Contact Info

Product

Resources

About